Arrivent Biopharma Common Stock Price Prediction
| AVBP Stock | 23.04 0.56 2.37% |
Momentum 45
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (0.79) | EPS Estimate Current Year (4.29) | EPS Estimate Next Year (3.91) | Wall Street Target Price 40.2333 | EPS Estimate Current Quarter (0.78) |
Using ArriVent BioPharma hype-based prediction, you can estimate the value of ArriVent BioPharma Common from the perspective of ArriVent BioPharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards ArriVent BioPharma using ArriVent BioPharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards ArriVent using crowd psychology based on the activity and movement of ArriVent BioPharma's stock price.
ArriVent BioPharma Implied Volatility | 2.78 |
ArriVent BioPharma's implied volatility exposes the market's sentiment of ArriVent BioPharma Common stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if ArriVent BioPharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that ArriVent BioPharma stock will not fluctuate a lot when ArriVent BioPharma's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in ArriVent BioPharma to buy its stock at a price that has no basis in reality. In that case, they are not buying ArriVent because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
ArriVent BioPharma after-hype prediction price | USD 23.52 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current ArriVent contract
Based on the Rule 16, the options market is currently suggesting that ArriVent BioPharma Common will have an average daily up or down price movement of about 0.17% per day over the life of the 2026-04-17 option contract. With ArriVent BioPharma trading at USD 23.04, that is roughly USD 0.04 . If you think that the market is fully incorporating ArriVent BioPharma's daily price movement you should consider acquiring ArriVent BioPharma Common options at the current volatility level of 2.78%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out ArriVent BioPharma Basic Forecasting Models to cross-verify your projections. ArriVent BioPharma After-Hype Price Density Analysis
As far as predicting the price of ArriVent BioPharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in ArriVent BioPharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of ArriVent BioPharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
ArriVent BioPharma Estimiated After-Hype Price Volatility
In the context of predicting ArriVent BioPharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on ArriVent BioPharma's historical news coverage. ArriVent BioPharma's after-hype downside and upside margins for the prediction period are 19.53 and 27.51, respectively. We have considered ArriVent BioPharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
ArriVent BioPharma is not too volatile at this time. Analysis and calculation of next after-hype price of ArriVent BioPharma Common is based on 3 months time horizon.
ArriVent BioPharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as ArriVent BioPharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ArriVent BioPharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with ArriVent BioPharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.46 | 3.99 | 0.08 | 0.06 | 4 Events / Month | 7 Events / Month | In about 4 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
23.04 | 23.52 | 0.34 |
|
ArriVent BioPharma Hype Timeline
ArriVent BioPharma Common is presently traded for 23.04. The entity has historical hype elasticity of -0.08, and average elasticity to hype of competition of -0.06. ArriVent is forecasted to decline in value after the next headline, with the price expected to drop to 23.52. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.34%, whereas the daily expected return is presently at 0.46%. The volatility of related hype on ArriVent BioPharma is about 2912.41%, with the expected price after the next announcement by competition of 22.98. About 99.0% of the company shares are held by institutions such as insurance companies. The book value of ArriVent BioPharma was presently reported as 7.47. The company recorded a loss per share of 4.15. ArriVent BioPharma Common had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in about 4 days. Check out ArriVent BioPharma Basic Forecasting Models to cross-verify your projections.ArriVent BioPharma Related Hype Analysis
Having access to credible news sources related to ArriVent BioPharma's direct competition is more important than ever and may enhance your ability to predict ArriVent BioPharma's future price movements. Getting to know how ArriVent BioPharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how ArriVent BioPharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| MGTX | MeiraGTx Holdings PLC | (0.37) | 8 per month | 0.00 | (0.08) | 5.08 | (5.54) | 14.00 | |
| REPL | Replimune Group | (0.09) | 9 per month | 0.00 | (0.03) | 5.56 | (5.32) | 20.44 | |
| ATXS | Astria Therapeutics | (0.02) | 6 per month | 1.00 | (0.0003) | 2.11 | (1.67) | 6.54 | |
| MBX | MBX Biosciences Common | (2.48) | 9 per month | 3.99 | 0.23 | 14.40 | (7.47) | 29.11 | |
| DNA | Ginkgo Bioworks Holdings | 0.18 | 10 per month | 0.00 | (0.08) | 8.16 | (6.79) | 28.96 | |
| IOVA | Iovance Biotherapeutics | (0.01) | 10 per month | 4.07 | 0.08 | 11.81 | (7.38) | 37.34 | |
| VALN | Valneva SE ADR | 0.82 | 3 per month | 0.00 | (0.05) | 4.83 | (4.81) | 15.32 | |
| ERAS | Erasca Inc | 1.46 | 9 per month | 2.66 | 0.30 | 15.04 | (4.76) | 50.26 | |
| ARVN | Arvinas | (0.42) | 6 per month | 3.09 | 0.12 | 5.91 | (4.42) | 28.90 | |
| DAWN | Day One Biopharmaceuticals | (0.44) | 10 per month | 3.53 | 0.13 | 13.81 | (6.53) | 39.62 |
ArriVent BioPharma Additional Predictive Modules
Most predictive techniques to examine ArriVent price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for ArriVent using various technical indicators. When you analyze ArriVent charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About ArriVent BioPharma Predictive Indicators
The successful prediction of ArriVent BioPharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as ArriVent BioPharma Common, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of ArriVent BioPharma based on analysis of ArriVent BioPharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to ArriVent BioPharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to ArriVent BioPharma's related companies. | 2024 | 2025 | 2026 (projected) | Current Ratio | 13.14 | 15.11 | 19.9 | Net Debt To EBITDA | 0.92 | 0.83 | 0.98 |
Pair Trading with ArriVent BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against ArriVent Stock
| 0.57 | VINC | Vincerx Pharma Common | PairCorr |
| 0.41 | DRMA | Dermata Therapeutics Trending | PairCorr |
| 0.37 | REVB | Revelation Biosciences | PairCorr |
| 0.37 | AMRN | Amarin PLC | PairCorr |
The ability to find closely correlated positions to ArriVent BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma Common to buy it.
The correlation of ArriVent BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ArriVent BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma's price analysis, check to measure ArriVent BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma is operating at the current time. Most of ArriVent BioPharma's value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma's price. Additionally, you may evaluate how the addition of ArriVent BioPharma to your portfolios can decrease your overall portfolio volatility.